Summary Summary Short summary of a recent publication, written by scientific experts. Published: 05 Mar 2020

Soluble TREM2 and CSF biomarkers of Alzheimer’s disease in those with Parkinson’s disease

Takeaway

  • In those with Parkinson’s disease (PD) with normal cognition or mild cognitive impairment (MCI), cerebrospinal fluid (CSF) soluble form of the triggering receptor expressed on myeloid cells 2 (sTREM2) concentration increases for those with elevated CSF tau, but not in those with elevated amyloid beta (Aβ).

Why this matters

    CSF sTREM2 may be used as a biomarker of TREM2-mediated microglia function and neuronal injury in those with PD.